{"id":"saralasin","rwe":[],"tags":[{"label":"saralasin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Type-2 angiotensin II receptor","category":"target"},{"label":"AGTR2","category":"gene"},{"label":"AGTR1","category":"gene"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Procter And Gamble","category":"company"},{"label":"Angiotensin II Type 1 Receptor Blockers","category":"pharmacology"},{"label":"Angiotensin Receptor Antagonists","category":"pharmacology"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Procter And Gamble","patents":[],"pricing":[],"allNames":"aralasin","offLabel":[],"synonyms":["saralasin acetate","saralasin acetate hydrate","saralasin","aralasin"],"timeline":[],"aiSummary":"Aralasin (SARALASIN) is a small molecule drug developed by Procter and Gamble that targets the type-2 angiotensin II receptor. It is classified as a saralasin and works by blocking the action of angiotensin II, a hormone that constricts blood vessels and increases blood pressure. However, it is not FDA-approved for any indications and is currently off-patent. As a result, there are no generic manufacturers of Aralasin. Its commercial status and safety considerations are limited due to its off-patent status.","approvals":[{"date":"","orphan":false,"company":"PROCTER AND GAMBLE","regulator":"FDA"}],"brandName":"Aralasin","ecosystem":[],"mechanism":{"target":"Type-2 angiotensin II receptor, Type-1 angiotensin II receptor, Angiotensin II receptor (AT-1) type-1","novelty":"First-in-class","targets":[{"gene":"AGTR2","source":"DrugCentral","target":"Type-2 angiotensin II receptor","protein":"Type-2 angiotensin II receptor"},{"gene":"AGTR1","source":"DrugCentral","target":"Type-1 angiotensin II receptor","protein":"Type-1 angiotensin II receptor"}],"modality":"Small Molecule","drugClass":"saralasin","explanation":"Think of angiotensin II like a key that unlocks blood vessels, making them narrower and increasing blood pressure. Aralasin is like a lock that blocks this key, preventing blood vessels from constricting and reducing blood pressure. This can help people with high blood pressure by making it easier for blood to flow through their blood vessels.","oneSentence":"Aralasin works by blocking the action of angiotensin II, a hormone that constricts blood vessels and increases blood pressure.","technicalDetail":"Aralasin is a competitive antagonist of the type-2 angiotensin II receptor, which is a G-protein coupled receptor that plays a crucial role in the renin-angiotensin-aldosterone system (RAAS). By blocking this receptor, Aralasin inhibits the vasoconstrictive and aldosterone-secreting effects of angiotensin II, leading to vasodilation and decreased blood pressure."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3542","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SARALASIN","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T15:35:19.820527","biosimilars":[],"competitors":[{"drugName":"angiotensin II","drugSlug":"angiotensin-ii","fdaApproval":"2017-12-21","patentExpiry":"Nov 20, 2030","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"azilsartan medoxomil","drugSlug":"azilsartan-medoxomil","fdaApproval":"2011-02-25","relationship":"same-target"},{"drugName":"candesartan cilexetil","drugSlug":"candesartan-cilexetil","fdaApproval":"1998-06-04","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"eprosartan","drugSlug":"eprosartan","fdaApproval":"1997-12-22","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"irbesartan","drugSlug":"irbesartan","fdaApproval":"1997-09-30","genericCount":23,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"losartan","drugSlug":"losartan","fdaApproval":"1995-04-14","patentExpiry":"Oct 7, 2041","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"olmesartan medoxomil","drugSlug":"olmesartan-medoxomil","fdaApproval":"2002-04-25","genericCount":25,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"sparsentan","drugSlug":"sparsentan","fdaApproval":"2023-02-17","patentExpiry":"Mar 29, 2030","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"telmisartan","drugSlug":"telmisartan","fdaApproval":"1998-11-10","genericCount":18,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"valsartan","drugSlug":"valsartan","fdaApproval":"1996-12-23","genericCount":22,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"saralasin","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"angiotensin-ii","brandName":"angiotensin II","genericName":"angiotensin II","approvalYear":"2017","relationship":"same-target"},{"drugId":"azilsartan-medoxomil","brandName":"azilsartan medoxomil","genericName":"azilsartan medoxomil","approvalYear":"2011","relationship":"same-target"},{"drugId":"candesartan-cilexetil","brandName":"candesartan cilexetil","genericName":"candesartan cilexetil","approvalYear":"1998","relationship":"same-target"},{"drugId":"eprosartan","brandName":"eprosartan","genericName":"eprosartan","approvalYear":"1997","relationship":"same-target"},{"drugId":"irbesartan","brandName":"irbesartan","genericName":"irbesartan","approvalYear":"1997","relationship":"same-target"},{"drugId":"losartan","brandName":"losartan","genericName":"losartan","approvalYear":"1995","relationship":"same-target"},{"drugId":"olmesartan-medoxomil","brandName":"olmesartan medoxomil","genericName":"olmesartan medoxomil","approvalYear":"2002","relationship":"same-target"},{"drugId":"sparsentan","brandName":"sparsentan","genericName":"sparsentan","approvalYear":"2023","relationship":"same-target"},{"drugId":"telmisartan","brandName":"telmisartan","genericName":"telmisartan","approvalYear":"1998","relationship":"same-target"},{"drugId":"valsartan","brandName":"valsartan","genericName":"valsartan","approvalYear":"1996","relationship":"same-target"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"_patentsChecked":true,"crossReferences":{"NDDF":"000667","UNII":"H2AFV2HE66","CHEBI":"CHEBI:135894","INN_ID":"3484","RXNORM":"7830","UMLSCUI":"C0036193","ChEMBL_ID":"CHEMBL938","KEGG_DRUG":"D04126","DRUGBANK_ID":"DB06763","PUBCHEM_CID":"6324663","IUPHAR_LIGAND_ID":"598","SECONDARY_CAS_RN":"39698-78-7","MESH_DESCRIPTOR_UI":"D012504"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Procter And Gamble","relationship":"Original Developer"}],"publicationCount":1297,"therapeuticAreas":["Hematology"],"biosimilarFilings":[],"originalDeveloper":"Procter And Gamble","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Procter And Gamble","companyId":"procter-and-gamble","modality":"Recombinant protein","firstApprovalDate":"1982","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"PROCTER AND GAMBLE","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"enriching","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}